EAN 2022 | Advances in Parkinson’s disease biomarkers

Carlo Colosimo, MD, Santa Maria University Hospital, Terni, Italy, shares advances in the field of biomarkers to improve the early identification of Parkinson’s disease. Changes in the brain before the onset of motor symptoms can already be identified by using dopamine transporter (DAT) imaging or by indirectly looking at the myocardial noradrenergic innervations through cardiac sympathetic neuroimaging. Additionally, various tissue- and fluid-based biomarkers are currently being investigated, including alpha-synuclein or other proteins in the cerebrospinal fluid and skin biomarkers obtained through biopsies. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.